{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Romidepsin+14+MG%2FM2", "query": { "intervention": "Romidepsin 14 MG/M2" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Romidepsin+14+MG%2FM2&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T07:57:01.039Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03547700", "title": "Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, T-Cell, Peripheral" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-09-26", "completion_date": "2020-08-27", "has_results": true, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-28T07:57:01.039Z", "location_count": 7, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547700" }, { "nct_id": "NCT04639843", "title": "Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult T-cell Leukemia/Lymphoma", "Extranodal NK-/T-cell Lymphoma, Nasal Type", "Enteropathy-Associated T-Cell Lymphoma", "Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma", "Hepatosplenic T-cell Lymphoma" ], "interventions": [ { "name": "CC-486 (5-azacitidine)", "type": "DRUG" }, { "name": "Duvelisib", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-11-03", "completion_date": "2022-11-03", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-09-28T07:57:01.039Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04639843" }, { "nct_id": "NCT00426764", "title": "A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2007-06-19", "completion_date": "2018-05-17", "has_results": true, "last_update_posted_date": "2020-02-11", "last_synced_at": "2026-09-28T07:57:01.039Z", "location_count": 45, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 35 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00426764" }, { "nct_id": "NCT01902225", "title": "Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "T-Cell Lymphoma", "Cutaneous Lymphoma" ], "interventions": [ { "name": "Istodax", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weiyun Ai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2014-03-04", "completion_date": "2020-04-11", "has_results": false, "last_update_posted_date": "2020-06-09", "last_synced_at": "2026-09-28T07:57:01.039Z", "location_count": 2, "location_summary": "San Francisco, California • Columbus, Ohio", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01902225" }, { "nct_id": "NCT02512172", "title": "A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Oral CC-486", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "MK-3475", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2016-02-19", "completion_date": "2021-11-20", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-09-28T07:57:01.039Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02512172" }, { "nct_id": "NCT01324323", "title": "Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancy", "Malignant Lymphoma" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2011-04-01", "completion_date": "2012-03-01", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-09-28T07:57:01.039Z", "location_count": 2, "location_summary": "Sarasota, Florida • Nashville, Tennessee", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01324323" }, { "nct_id": "NCT04747236", "title": "Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PTCL" ], "interventions": [ { "name": "Azacytidine", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "Belinostat", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-02-19", "completion_date": "2030-06-02", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-09-28T07:57:01.039Z", "location_count": 6, "location_summary": "Long Beach, California • New Haven, Connecticut • New York, New York + 3 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04747236" }, { "nct_id": "NCT01998035", "title": "Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoid Malignancies", "Lymphoma", "Hodgkin Lymphoma", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "RomiDEPsin 10 MG/M2", "type": "DRUG" }, { "name": "Oral 5-Azacitidine 100 MG", "type": "DRUG" }, { "name": "Romidepsin 14 MG/M2", "type": "DRUG" }, { "name": "Oral 5-Azacitidine 200 MG", "type": "DRUG" }, { "name": "Oral 5-Azacitidine 300 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2013-11", "completion_date": "2020-01-06", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-09-28T07:57:01.039Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998035" }, { "nct_id": "NCT02616965", "title": "A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T-cell Lymphoma (CTCL)" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2017-02-22", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-09-28T07:57:01.039Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02616965" }, { "nct_id": "NCT01933594", "title": "Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Placebo for Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2014-05-05", "completion_date": "2018-04-16", "has_results": true, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-28T07:57:01.039Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01933594" } ] }